Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
Hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been shown to improve outcomes in these patients. However, women in rural and underserved communities often face significant barriers such as oncologist shortages and geographic barriers, leading to disparities in care. This CME/CE activity will cover current and emerging treatment options for HR+/HER2- early breast cancer and the latest guidance on how to integrate biomarker and genetic testing into clinical practice. Expert faculty will also share collaborative strategies to improve early breast cancer care and management in rural and underserved settings.

This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Integrate clinical evidence and current guidance on biomarker and genetic testing into management of HR+/HER2- early breast cancer
Evaluate the efficacy and safety of current and emerging therapies for HR+/HER2- early breast cancer
Develop personalized treatment plans for patients with HR+/HER2- early breast cancer based on patient and disease characteristics
Discuss interprofessional strategies for improving early breast cancer care and management in rural and underserved settings
Faculty